University of Gothenburg Researchers Identify ATF4 Protein as Key Driver of Lung Cancer Metastasis in Older Patients; Discovery Solves the "Slow-Growth Paradox"

Researchers identify ATF4 as a protein hijacked by lung cancer in older patients to promote metastasis, offering a new target for precision medicine.

By: AXL Media

Published: Mar 13, 2026, 7:19 AM EDT

Source: Information for this report was sourced from University of Gothenburg

Solving the Paradox of the Aging Tumor

Lung cancer remains a disease that primarily affects the elderly, yet most laboratory research is conducted using young animal models that do not reflect the biological realities of aging. To bridge this gap, researchers at the University of Gothenburg compared lung tumors in young and old mice while simultaneously analyzing clinical data from over 1,000 patients in Sweden. The study, published in Nature, successfully explains a long-standing medical paradox: older patients frequently present with primary tumors that are small and grow slowly, yet have already metastasized to the brain, liver, or bones. The research identifies a specific protein, ATF4, as the culprit behind this aggressive spread.

The Hijacking of the Integrated Stress Response

Under normal conditions, the ATF4 protein serves as a critical hub for the "integrated stress response," helping cells survive nutrient deprivation or viral infections by activating protective measures. However, in older patients, lung cancer cells hijack this system. Instead of using ATF4 for protection, the tumor uses it to reprogram its metabolism. This metabolic rewiring does not accelerate the tumor's growth rate; instead, it provides the cancer cells with the energy and flexibility needed to break away from the primary site and form colonies in other parts of the body.

ATF4 as a Biomarker for Aggressive Disease

The research team, led by Associate Professors Volkan Sayin and Clotilde Wiel, found that tumors in both older mice and human patients exhibited significantly higher levels of ATF4. These elevated levels were directly correlated with a higher risk of recurrence after surgery and overall poorer survival rates among patients with lung adenocarcinoma, the most common form of the disease. Consequently, ATF4 is being hailed not only as a driver of metastasis but also as a vital biomarker that can help physicians identify which older patients are at the highest risk for aggressive, systemic spread.